Preparation of topical itraconazole with enhanced skin/nail permeability and in vivo antifungal efficacy against superficial mycosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Subedi, L. | - |
dc.contributor.author | Song, S.-Y. | - |
dc.contributor.author | Jha, S.K. | - |
dc.contributor.author | Lee, S.-H. | - |
dc.contributor.author | Pangeni, R. | - |
dc.contributor.author | Koo, K.-T. | - |
dc.contributor.author | Kim, B.J. | - |
dc.contributor.author | Cho, S.-S. | - |
dc.contributor.author | Park, J.W. | - |
dc.date.accessioned | 2021-07-29T05:40:10Z | - |
dc.date.available | 2021-07-29T05:40:10Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/48001 | - |
dc.description.abstract | In this study, a stable and highly skin-permeable topical delivery system for itraconazole (ITZ) was designed to provide effective treatment against superficial mycosis. Herein, ITZ was incorporated into a solution composed of ethanol, benzyl alcohol, hydrochloric acid, Transcutol P, and cyclomethicone as a delivery vehicle, solubilizer, protonating agent, permeation enhancer, and spreading agent, respectively. At 72 h, the optimal topical ITZ formulation (ITZ–TF#11) exhibited 135% enhanced skin permeability, which led to increases in drug deposition in the stratum corneum, epidermis, and dermis of 479%, 739%, and 2024%, respectively, compared with the deposition of 1% ITZ in ethanol (control). Moreover, on day 7, ITZ–TF#11 demonstrated 2.09-and 2.30-fold enhanced nail flux and drug deposition, compared with the control. At a dose of 40 mg/kg/day, ITZ–TF#11 showed 323% greater lesion recovery, a 165% lower mean erythema severity score, and a 37% lower mean logarithm of viable fungal cells in skin in the treated area, compared with mice that received oral ITZ at the same dose. Overall, the findings imply that ITZ–TF#11 is a superior alternative to oral ITZ for treatment of superficial mycosis. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.format.extent | 16 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Preparation of topical itraconazole with enhanced skin/nail permeability and in vivo antifungal efficacy against superficial mycosis | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/pharmaceutics13050622 | - |
dc.identifier.bibliographicCitation | Pharmaceutics, v.13, no.5, pp 1 - 16 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000662451800001 | - |
dc.identifier.scopusid | 2-s2.0-85105541284 | - |
dc.citation.endPage | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Pharmaceutics | - |
dc.citation.volume | 13 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Antifungal activity | - |
dc.subject.keywordAuthor | Itraconazole | - |
dc.subject.keywordAuthor | Nail infiltration | - |
dc.subject.keywordAuthor | Skin penetration | - |
dc.subject.keywordAuthor | Superficial mycosis | - |
dc.subject.keywordAuthor | Topical solution | - |
dc.subject.keywordPlus | SKIN | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | FORMULATION | - |
dc.subject.keywordPlus | AGENTS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.